Ask AI

mTNBC Practice Readiness: Applying Current Standards and Interpreting Emerging First-line TROP2 ADC Evidence for Immunotherapy-Ineligible Patients

Slideset

Released: September 08, 2026

See Activity Collection

Explore current and emerging phase III evidence for TROP2 ADCs in patients with metastatic triple-negative breast cancer who are ineligible for immunotherapy, including implications for patients and healthcare teams when selecting first-line and later-line treatments. Examine how patient characteristics, prior treatment exposure, comorbidities, and distinct adverse event profiles inform individualized care, along with multidisciplinary strategies for toxicity prevention, monitoring, supportive care, and dose modification.

TROP2 ADCs in mTNBC

Activity Information

Released: September 08, 2026